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Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but
development of resistance in patients is common. In this issue ofCell, Croci et al. identify a complex
set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2
(VEGFR2) and stimulates VEGF-independent tumor angiogenesis.Angiogenesis in tumors has long been a
target of cancer therapy, and anti-VEGF
antibodies such as Bevacizumab are
currently in use in cancer treatment
(Abdollahi and Folkman, 2010). Though
anti-VEGF immunotherapy is usually
effective as a neo-adjuvant, it often fails
when tumors become refractory to
continued treatment (Welti et al., 2013).
Mechanisms by which tumor angio-
genesis may proceed in the presence of
anti-VEGF have been identified. For
example, G-CSF produced from tumor
and stromal cells, recruits myeloid cells
into tumors, promotes their expansion,
and activates proangiogenic pathways
(Phan et al., 2013). In this issue of Cell,
Croci et al. (2014) identify another mecha-
nism by which galectin-1 specifically
promotes tumor progression in anti-
VEGF-A refractory tumors.
Galectins belong to a family of mamma-
lian glycan-binding proteins that recog-
nize glycans attached to glycoproteins
and glycopipids (Thijssen et al., 2013).
There are 14 human galectins defined by
their ability to bind galactose (Gal) resi-
dues in glycans, and the inhibition of that
binding by lactose. Galectin-1 has a mo-
lecular weight of 14.5 kDa and occurs
as a dimer. It has a single carbohydrate
recognition domain (CRD) and, conse-
quently, each dimer is divalent for glycan
binding. Therefore, galectin-1 may cross-
link glycans within a glycoprotein or gly-
cans residing on adjacent glycoproteins,
either on the same cell or on a neighboring
cell. Galectin crosslinking serves to retain
glycoproteins on the cell surface, pro-
longing cell-surface residency of cytokine
and growth factor receptors, and thereby
affecting signaling strength or duration
(Lau et al., 2007; Boscher et al., 2011).Rabinovich and colleagues have
recently identified roles for galectin-1 in
prostate cancer (Laderach et al., 2013)
and Kaposi’s sarcoma (Croci et al.,
2012). In the case of prostate cancer,
galectin-1 is the most highly expressed
of ten galectins examined in human pros-
tate cancer cell lines, and expression
increases with prostate cancer stage or
tumor progression. By contrast, expres-
sion of galectin-3, -4, -9, and -12
decreases with prostate tumor pro-
gression. Galectin-1 is predominantly ex-
pressed at the tumor-vascular interface,
and increased expression correlates
with increased tumor vascularization.
Silencing of galectin-1 in tumor cells
reduces tumor angiogenesis in mouse
models (Laderach et al., 2013). A similar
role for galectin-1 was observed in
Kaposi’s sarcomas. In this case, the virus
KSHV and hypoxia were shown to induce
galectin-1 secretion following upregula-
tion of NFkB. Both hypoxia and galectin-
1 then stimulate tumor angiogenesis that
enhances tumor growth. Importantly,
treatment with an anti-galectin-1 antibody
could suppress tumors that had already
developed in the mouse (Croci et al.,
2012). In this issue, Croci et al. (2014)
provide new mechanistic insights into
galectin-1’s roles in promoting tumor
angiogenesis and progression in anti-
VEGF-A refractory tumors.
In sensitive tumor cell lines, growth and
angiogenesis are inhibited by anti-VEGF-
A treatment, whereas both proliferation
and angiogenesis increase in cell lines
that are refractory to antibody treatment.
Refractory, but not sensitive, tumors
secrete increased amounts of galectin-1
during anti-VEGF-A treatment, and this
treatment also alters the glycans ex-Cell 156,pressed by endothelial cells (ECs) (their
glycophenotype) in refractory tumors. A
similar effect on EC glycophenotype is
caused by conditioned medium from
refractory tumor cells cultured under
hypoxic conditions. The alterations
induced in the glycans of ECs by these
conditions lead to an increase in neutral,
complex N-glycans (Figure 1). Branched
N-glycans that contain repeating units
of Gal-GlcNAc (polylactosamine) and
terminate in Gal are preferred ligands of
galectin-1 (Stowell et al., 2008). There-
fore, conditions in which VEGF is inacti-
vated by antibody treatment, and the
tumor microenvironment is hypoxic,
cause tumor cells to secrete galectin-1
and ECs to generate neutral, complex
N-glycans that bind galectin-1 (Figure 1).
VEGFR2 has many potential complex
N-glycan sites (Figure 1). Site-directed
mutagenesis identifies the N-glycans on
IgG domains 3, 4, and 7 as necessary
for galectin-1 to bind optimally to
VEGFR2. Functionality of galectin-1
binding has been shown by knockdown
of galectin-1 in tumor cells. Galectin-1
removal reduces tumor cell growth and
angiogenesis, but only for refractory
tumors treated with anti-VEGF-A. ECs
respond to hypoxia and proinflammatory
cytokines including FGF2, TGFb, and
IL10 by reducing sialic acid residues on
N-glycans, and increasing the expres-
sion of branched, complex N-glycans
containing polylactosamine extensions
(Figure 1).
MGAT5, a glycosyltranferase that initi-
ates a key branch of complex N-glycans,
promotes galectin-1 binding, whereas
galectin-1 does not bind to glycans
capped with a2,6-linked sialic acid,
added by the sialyltransferase ST6GAL1February 13, 2014 ª2014 Elsevier Inc. 625
Figure 1. Anti-VEGF Treatment Induces Galectin-1 from Tumor Cells to Stimulate VEGFR2 and Angiogenesis
Tumors refractory to anti-VEGF treatment in vivo exhibit enhanced angiogenesis in response to anti-VEGF-A treatment. Both anti-VEGF treatment and hypoxia
markedly increase galectin-1 secretion from tumor cells. Galectin-1 binds to complex N-glycans on endothelial cell (EC) glycoproteins, including VEGFR2, and
especially to the N-glycans in Ig domains 3, 4, and 7 of VEGFR2. Binding is enhanced by proinflammatory cytokines such as FGF2, IL10, and TGFbwhose action
on ECs causes changes in the synthesis of complex N-glycans due to upregulation of MGAT5 and downregulation of ST6GAL-1 glycosyltransferases. Under
normoxic conditions in the presence of anti-inflammatory cytokines, complex N-glycans on EC glycoproteins are mostly terminated in sialic acid and have fewer
polylactosamine extensions. By contrast, under hypoxic conditions or following treatment with proinflammatory cytokines, EC glycoproteins carry neutral,
complex N-glycans that mainly lack sialic acid, and have longer polylactosamine extensions. As a result, more galectin-1 bindsmore avidly to VEGFR2 N-glycans
under these conditions. Being dimeric, galectin-1 may interact with adjacent glycans with Gal residues serving to crosslink VEGFR2. The residency time of
VEGFR2 on the cell surface is prolonged 3-fold by galectin-1, even in the presence of VEGF-A. Therefore, hypoxia, anti-VEGF treatment and the presence of
proinflammatory cytokines combine to promote VEGF-independent angiogenesis that stimulates tumor progression.(Figure 1). In an elegant set of experi-
ments, Croci et al. convert refractory
tumors to sensitivity to anti-VEGF-A by
establishing them in an Mgat5 knockout
mouse. In the absence of MGAT5,
N-glycans on VEGFR2 bind insufficient
galectin-1 to promote angiogenesis and
thus tumor growth decreases. Con-
versely, when tumors sensitive to anti-
VEGF-A treatment are grown in mice
lacking ST6Gal1, they are converted to
refractory tumors because N-glycans on
VEGFR2 lack a2,6-linked sialic acid
caps and bind galectin-1 much better,
thereby promoting angiogenesis and
tumor growth.
Both galectin-1 and VEGF cause
increased phosphorylation of VEGFR2,
Akt, and ERK1/2. Tube formation and EC
binding induced by galectin-1 can be
inhibited by anti-VEGFR2, but not anti-
VEGFR1, VEGFR3, or several integrin anti-
bodies. In addition, galectin-1, which does
not inhibit VEGF binding, causes VEGFR2
to segregate into clusters on the cell sur-
face, and this does not occur following
knockdown of MGAT5. Finally, compared
to VEGF that stimulates endocytosis of
VEGFR2 within 5–10 min, galectin-1 sig-626 Cell 156, February 13, 2014 ª2014 Elsevnificantly prolongs the cell-surface resi-
dency time of VEGFR2. Therefore, within
tumors treatedwith anti-VEGF-A, hypoxia,
and proinflammatory cytokines in the
microenvironment cause tumor cells to
secrete galectin-1 and ECs to enhance
their galectin-1-binding abilities, respec-
tively, leading to galectin-1-induced
angiogenesis that promotes tumor pro-
gression. The importance of galectin-1 to
this mechanism has been demonstrated
by the fact that secretion of galectin-1,
but not galectin-3 or -8 angiogenic galec-
tins, is induced, and treatment with a
galectin-1-neutralizing antibody specif-
ically prevents galectin-1-induced angio-
genesis. Mice treated with anti-galectin-1
exhibit greatly reduced angiogenesis and
tumor growth in anti-VEGF-A refractory,
and to some extent in anti-VEGF-A-sensi-
tive, tumors. Thus, anti-galectin-1 treat-
ment should be considered as a strategy
to inhibit tumor angiogenesis in combina-
tion with anti-VEGF-A treatment.REFERENCES
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